Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Payables (2017 - 2025)

Historic Payables for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $13.6 million.

  • Innate Pharma's Payables fell 2026.22% to $13.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $13.6 million, marking a year-over-year decrease of 2026.22%. This contributed to the annual value of $17.1 million for FY2024, which is 658.28% down from last year.
  • Latest data reveals that Innate Pharma reported Payables of $13.6 million as of Q2 2025, which was down 2026.22% from $17.1 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Payables registered a high of $32.7 million during Q4 2021, and its lowest value of $13.6 million during Q2 2025.
  • Moreover, its 5-year median value for Payables was $19.9 million (2022), whereas its average is $20.1 million.
  • In the last 5 years, Innate Pharma's Payables tumbled by 9992.28% in 2021 and then skyrocketed by 382.06% in 2023.
  • Quarter analysis of 5 years shows Innate Pharma's Payables stood at $32.7 million in 2021, then plummeted by 34.73% to $21.3 million in 2022, then decreased by 14.17% to $18.3 million in 2023, then dropped by 6.58% to $17.1 million in 2024, then decreased by 20.32% to $13.6 million in 2025.
  • Its Payables stands at $13.6 million for Q2 2025, versus $17.1 million for Q4 2024 and $17.1 million for Q2 2024.